Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
Derazantinib is a multi-kinase inhibitor.1 It is a pan inhibitor of FGF receptors (FGFRs; IC50s = 4.5, 1.8, 4.5, and 34 nM for FGFR1, -2, -3, and -4, respectively) and also inhibits 10 receptor tyrosine kinases, 8 non-receptor tyrosine kinases, and the calcium/calmodulin-dependent protein kinase QIK in a panel of 297 kinases (IC50s = 3-31 and 9.7 nM, respectively). Derazantinib decreases phosphorylation of FGFR in COS-1 cells expressing FGFR1, -2, -3, or -4 (IC50s = <0.123, 0.185, 0.463, and >10 µM, respectively) and inhibits the growth of 15 cancer cell lines with mutant, amplified, or translocated FGFR (GI50s = 0.1-1.7 µM). It reduces tumor growth and decreases tumor protein levels of phosphorylated FGFR, FGFR substrate 2 (FRS2), and ERK in a SNU-16 mouse xenograft model when administered at doses of 50 and 75 mg/kg.
WARNING This product is not for human or veterinary use.
1. Preclinical activity of ARQ 087, a novel inhibitor targeting FGFR dysregulation. PLoS One 11(9), e0162594 (2016).